Borneol-mediated vardenafil hydrochloride patch for pediatric pulmonary arterial hypertension: Preparation, characterization and in vivo study

• Published in: International journal of pharmaceutics Vol. 591; p. 119864
• Main Authors: Jiang, Dong, Tan, Huajin, Zhang, Rujiao, Wang, Kaikang, Zhang, Yujia, Tan, Xiaochuan, Zheng, Wensheng
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 15.12.2020
• Subjects: Borneol; Patch; Pediatric pulmonary arterial hypertension; Transdermal delivery system; Vardenafil hydrochloride; Transdermal delivery system; Pediatric pulmonary arterial hypertension; Vardenafil hydrochloride; Patch; Borneol
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2020.119864

[Display omitted] Pediatric pulmonary arterial hypertension (PPAH) is a malignant progressive rare disease characterized by restricted pulmonary artery blood flow and progressively increasing blood pressure, which has shorter survival time of only about 10 months as compared to adults. Previous studies have shown that low-dose vardenafil hydrochloride (Var) could significantly improve the symptoms of PPAH. However, Var is currently available only in tablet form in the market for erectile dysfunction, and no special preparation is available for PPAH. In this study, borneol-mediated vardenafil hydrochloride patch (BO-VarP) with sodium polyacrylate as the skeleton material was prepared by coating method, which was characterized by temperature resistance, formability, adhesive force, skin irritation and in vitro permeation. Blood concentration of optimized BO-VarP was measured by LC-MS/MS using intragastric administration (i.g.) as a control, and pharmacodynamic studies were conducted using a rat model of pulmonary arterial hypertension induced by monocrotaline. Optimized BO-VarP showed good appearance, with optimal temperature resistance and formability, appropriate adhesive force and low skin irritation, and its cumulative permeation flux was 14.9 times higher than patch without penetration enhancer. The blood concentration within therapeutic window of BO-VarP lasted longer than i.g., and BO-VarP could improve symptoms of PPAH by reducing pulmonary arterial pressure and right heart hypertrophy index. BO-VarP had good therapeutic effect in PPAH rats and suitable compliance in children, which provided a potential industrial transdermal delivery system for the treatment of PPAH.